Edward P Gelmann

List of Publications by Year
in descending order

89 papers	11,882 citations	44069 48 h-index	48315 88 g-index
90 all docs	90 docs citations	90 times ranked	11190 citing authors

#	Article	IF	Citations
1	Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine, 2009, 360, 1310-1319.	27.0	2,592
2	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genetics, 2007, 39, 645-649.	21.4	1,059
3	Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Contemporary Clinical Trials, 2000, 21, 273S-309S.	1.9	854
4	Molecular Biology of the Androgen Receptor. Journal of Clinical Oncology, 2002, 20, 3001-3015.	1.6	839
5	A Novel Human Prostate-Specific, Androgen-Regulated Homeobox Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate Cancer. Genomics, 1997, 43, 69-77.	2.9	331
6	p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 1993, 23, 123-134.	2.3	276
7	A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10991-10996.	7.1	261
8	Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell Lines. Molecular Endocrinology, 1987, 1, 216-223.	3.7	258
9	Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Research and Treatment, 1994, 31, 325-335.	2.5	257
10	Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Research and Treatment, 1986, 7, 59-70.	2.5	252
11	A survey of human leukaemias for sequences of a human retrovirus. Nature, 1983, 302, 626-628.	27.8	214
12	Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate, 1989, 14, 103-115.	2.3	205
13	Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial. Journal of the National Cancer Institute, 2005, 97, 433-438.	6.3	191
14	Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1985, 78, 417-422.	1.5	180
15	A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus. Nature, 1981, 292, 31-35.	27.8	171
16	Differential effects of transforming growth factor Î² on human prostate cancer cells in vitro. Molecular and Cellular Endocrinology, 1989, 62, 79-87.	3.2	165
17	Î²-Catenin Binds to the Activation Function 2 Region of the Androgen Receptor and Modulates the Effects of the N-Terminal Domain and TIF2 on Ligand-Dependent Transcription. Molecular and Cellular Biology, 2003, 23, 1674-1687.	2.3	163
18	Treatment of Cytomegalovirus Retinitis With Dihydroxy Propoxymethyl Guanine. American Journal of Ophthalmology, 1986, 101, 95-101.	3.3	155

#	Article	IF	Citations
19	Deletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate Cancer. Cancer Research, 2005, 65, 1164-1173.	0.9	153
20	Homology of human T-cell leukaemia virus envelope gene with class I HLA gene. Nature, 1983, 305, 60-62.	27.8	138
21	A Common 8q24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study. Cancer Research, 2007, 67, 2951-2956.	0.9	136
22	Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU International, 2008, 102, 1524-1530.	2.5	129
23	Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence. Clinical Cancer Research, 2005, 11, 5863-5868.	7.0	122
24	Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature, 1984, 310, 505-506.	27.8	115
25	Tissue microarray analysis reveals prognostic significance of syndecanâ€1 expression in prostate cancer. Prostate, 2003, 55, 20-29.	2.3	115
26	Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. American Journal of Medicine, 1985, 78, 737-741.	1.5	114
27	Identification of reciprocal translocation sites within the c-myc oncogene and immunoglobulin Î¼ locus in a Burkitt lymphoma. Nature, 1983, 306, 799-803.	27.8	113
28	Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation, 2008, 76, 717-727.	1.9	113
29	Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor. Molecular Endocrinology, 2004, 18, 70-85.	3.7	107
30	Mutant of Escherichia coli Deficient in the Synthesis of cis -Vaccenic Acid. Journal of Bacteriology, 1972, 112, 381-387.	2.2	102
31	Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. Cancer Research, 2008, 68, 236-248.	0.9	96
32	Quality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of the National Cancer Institute, 2004, 96, 1083-1094.	6.3	94
33	Expression of NKX3.1 in normal and malignant tissues. Prostate, 2003, 55, 111-117.	2.3	85
34	P53 gene mutations: Case study of a clinical marker for solid tumors. Seminars in Oncology, 2002, 29, 246-257.	2.2	71
35	Cross-regulation of signaling pathways: An example of nuclear hormone receptors and the canonical Wnt pathway. Experimental Cell Research, 2010, 316, 1763-1772.	2.6	69
36	Growth regulatory peptide production by human breast carcinoma cells. The Journal of Steroid Biochemistry, 1988, 30, 53-61.	1.1	68

#	Article	IF	Citations
37	Molecular biology of prostate-cancer pathogenesis. Current Opinion in Urology, 2006, 16, 123-131.	1.8	68
38	A phase II study of mifepristone (RUâ€486) in castrationâ€resistant prostate cancer, with a correlative assessment of androgenâ€related hormones. BJU International, 2008, 101, 1084-1089.	2.5	68
39	Combination chemotherapy of disseminated kaposi's sarcoma in patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1987, 82, 456-462.	1.5	65
40	NKX3.1 Activates Cellular Response to DNA Damage. Cancer Research, 2010, 70, 3089-3097.	0.9	64
41	DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. Nucleic Acids Research, 2000, 28, 2389-2395.	14.5	60
42	Inflammatory Cytokines Induce Phosphorylation and Ubiquitination of Prostate Suppressor Protein NKX3.1. Cancer Research, 2008, 68, 6896-6901.	0.9	59
43	Hairy cell leukemia: Association with disseminated atypical mycobacterial infection. Cancer, 1981, 48, 380-383.	4.1	58
44	v-rasHExpression Confers Hormone-Independentin VitroGrowth to LNCaP Prostate Carcinoma Cells. Molecular Endocrinology, 1991, 5, 209-216.	3.7	56
45	Alterations in Phosphoinositide Metabolism Associated with 17Î²-Estradiol and Growth Factor Treatment of MCF-7 Breast Cancer Cells. Molecular Endocrinology, 1988, 2, 159-166.	3.7	55
46	p53 Abnormalities in Primary Prostate Cancer: Single-Strand Conformation Polymorphism Analysis of Complementary DNA in Comparison With Genomic DNA. Journal of the National Cancer Institute, 1997, 89, 66-71.	6.3	55
47	The v-sis transforming gene of simian sarcoma virus is a new onc gene of primate origin. Nature, 1981, 294, 273-275.	27.8	51
48	Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome. Clinical Immunology and Immunopathology, 1985, 35, 43-46.	2.0	49
49	Interaction of Î²-Catenin and TIF2/GRIP1 in Transcriptional Activation by the Androgen Receptor. Journal of Biological Chemistry, 2005, 280, 37853-37867.	3.4	48
50	Germ-Line Mutation of NKX3.1 Cosegregates with Hereditary Prostate Cancer and Alters the Homeodomain Structure and Function. Cancer Research, 2006, 66, 69-77.	0.9	48
51	Tumor Necrosis Factor-Î± and Fas Activate Complementary Fas-associated Death Domain-dependent Pathways That Enhance Apoptosis Induced by Î³-Irradiation. Journal of Biological Chemistry, 2000, 275, 8610-8617.	3.4	46
52	NKX3.1 Homeodomain Protein Binds to Topoisomerase I and Enhances Its Activity. Cancer Research, 2007, 67, 455-464.	0.9	42
53	Retinoblastoma Protein-mediated Apoptosis After Î³-Irradiation. Journal of Biological Chemistry, 2002, 277, 44969-44979.	3.4	38
54	Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death and Differentiation, 1999, 6, 394-401.	11.2	36

#	Article	IF	Citations
55	Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Research, 2002, 62, 2654-9.	0.9	34
56	ROLE OF INTERFERON IN AIDS. Annals of the New York Academy of Sciences, 1984, 437, 65-75.	3.8	33
57	Functional Activation of ATM by the Prostate Cancer Suppressor NKX3.1. Cell Reports, 2013, 4, 516-529.	6.4	33
58	Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. BJU International, 2007, 99, 775-779.	2.5	32
59	NKX3.1 Suppresses TMPRSS2â€“ERG Gene Rearrangement and Mediates Repair of Androgen Receptorâ€“Induced DNA Damage. Cancer Research, 2015, 75, 2686-2698.	0.9	30
60	Complexities of Prostate-Cancer Risk. New England Journal of Medicine, 2008, 358, 961-963.	27.0	29
61	Invasive and metastatic properties of MCF-7 cells andrasH-transfected MCF-7 cell lines. International Journal of Cancer, 1992, 50, 665-669.	5.1	26
62	Indications for and Diagnostic Efficacy of Open-Lung Biopsy in the Patient with Acquired Immunodeficiency Syndrome (AIDS). Annals of Thoracic Surgery, 1986, 41, 307-312.	1.3	25
63	Physical and Functional Interactions between the Prostate Suppressor Homeoprotein NKX3.1 and Serum Response Factor. Journal of Molecular Biology, 2006, 360, 989-999.	4.2	23
64	Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer, 2004, 100, 300-307.	4.1	21
65	Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression. Cancer Research, 2019, 79, 4124-4134.	0.9	21
66	In Search of a Hodgkin's Disease Virus. New England Journal of Medicine, 1981, 304, 169-170.	27.0	20
67	Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology, 2001, 58, 561-566.	1.0	20
68	EXPRESSION OF GENES AND PROTEINS SPECIFIC FOR PROSTATE CANCER. Journal of Urology, 2004, 172, S23-6; discussion S26-7.	0.4	20
69	High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth. Prostate, 2012, 72, 1678-1687.	2.3	20
70	NKX3.1 Activates Expression of Insulin-like Growth Factor Binding Protein-3 to Mediate Insulin-like Growth Factor-I Signaling and Cell Proliferation. Cancer Research, 2009, 69, 2615-2622.	0.9	19
71	A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer, 1992, 69, 213-218.	4.1	18
72	The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase. Molecular Cancer Research, 2015, 13, 913-922.	3.4	18

#	Article	IF	Citations
73	Silencing Mediator for Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Attenuate Transcriptional Activation by the Î²-Catenin-TCF4 Complex. Journal of Biological Chemistry, 2008, 283, 25988-25999.	3.4	17
74	Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I. Biochemical Journal, 2013, 453, 125-136.	3.7	16
75	Nkx3.1 controls the DNA repair response in the mouse prostate. Prostate, 2016, 76, 402-408.	2.3	13
76	Phosphoinositide metabolism in human prostate cancer cells in vitro. Prostate, 1990, 16, 15-27.	2.3	8
77	DNA Testing to Refute a Diagnosis of Cancer. New England Journal of Medicine, 1997, 337, 1245-1247.	27.0	8
78	Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. Urology, 2006, 67, 311-315.	1.0	8
79	9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 398-403.	1.6	7
80	Searching for the gatekeeper oncogene of prostate cancer. Critical Reviews in Oncology/Hematology, 2003, 46, 11-20.	4.4	6
81	Interactions of The Acidic Domain and SRF Interacting Motifs with the NKX3.1 Homeodomain. Biochemistry, 2009, 48, 10601-10607.	2.5	6
82	Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression. PLoS ONE, 2018, 13, e0205837.	2.5	6
83	Receptor- and signal transductionrelated proto-oncogenes in breast cancer. Trends in Pharmacological Sciences, 1987, 8, 372-375.	8.7	3
84	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes and Cancer, 2013, 4, 535-545.	1.9	3
85	Treatment of the Prostate in the Presence of Metastases: Lessons from Other Solid Tumors. European Urology, 2016, 69, 795-796.	1.9	3
86	Clinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On. Annals of Internal Medicine, 2009, 150, 647.	3.9	3
87	Analysis of Peripheral Blood Lymphocytes of AIDS and High-Risk Patients for Human Cytomegalovirus Transforming DNA Sequences. Intervirology, 1991, 32, 10-18.	2.8	2
88	CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss. Cancer Research, 2020, 80, 4805-4814.	0.9	2
89	Two strains of baboon endogenous virus demonstrate a high degree of genetic conservation. Gene, 1983, 21, 161-164.	2.2	0